Edwards Lifesciences Corp Q2 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Maybe to start, TAVR is such a necessary procedure for these patients. And it's sad to see it slow down like this, but it's understandable given how many steps are involved in the patient population involved. What's your sense of what the early funnel is like? How are -- how's the early funnel with patient visits to doctors, diagnosis? Where is really the bottleneck that you're seeing? And how do you expect the funnel to play out in third and fourth quarter, both U.S. and outside the U.S.?

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Okay. And maybe as a follow-up on TMTT, it's not surprising given the euro exposure to see the guidance moved down there on a dollar basis. But this is also a market that's recovering probably slower than we had thought at the December Analyst Day. So maybe you could walk us through how much of it is PASCAL, and your product set versus the competition? And how much is the market? And how we should think about cadence there in third and fourth quarter? It still requires a step-up to reach the midpoint of guidance.

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : My first question is in terms of the U.S. TAVR and the number of centers, I think on the fourth quarter call, you said you had about 850 centers. I was wondering where you ended at the end of June. And kind of how should we think about center growth going forward? And then my second question is just on your SG&A spend was pretty high. It's a big jump sequentially. And I guess is a lot of that kind of the prebuild or the build of the infrastructure for PASCAL?